CMS proposal could speed drug prior authorization for patients

For many patients, the biggest practical effect of a new CMS proposal may be simple: fewer long waits when a drug needs prior authorization. The agency wants more of those requests handled electronically, with clearer standards for plans, doctors, and patients.

That could matter at the pharmacy counter. But this is still a proposal, not a final rule, so the details, timing, and final requirements could change.

What CMS is proposing

The Centers for Medicare & Medicaid Services says the rule would extend electronic prior authorization requirements to certain drugs, building on earlier CMS work that focused on non-drug items and services. CMS is also proposing shared standards so plans can receive more complete information in a standardized electronic format.

According to CMS, the proposal would apply to multiple coverage types, including Medicare Advantage, Medicaid and CHIP managed care, Medicaid and CHIP fee-for-service programs, and Affordable Care Act marketplace plans on the federal exchanges. For drugs covered under a medical benefit, CMS says the electronic prior authorization framework would be expanded to include coverage and documentation requirements.

What patients might notice

If the rule is finalized, patients may see fewer back-and-forth delays between a prescriber and a health plan. CMS says the goal is to speed decisions, improve transparency, and reduce administrative burden.

Patients might also get clearer information when a request is denied, and plan data could become easier to compare over time. But how that works in practice will still depend on each plan’s systems and operations.

Why this matters now

Prior authorization is already common. KFF reported that prior authorization remains widespread in Medicare Advantage, and that the process can vary a lot by insurer. That backdrop helps explain why CMS is targeting the system now.

Even when prior authorization is intended to control costs or verify medical need, it can also delay treatment, including prescriptions. For patients who need a drug quickly, those delays can be frustrating and sometimes disruptive.

What is still uncertain

This is still proposed rulemaking, so none of the new requirements are final yet. CMS can revise the language after public comments, and implementation dates could shift before anything takes effect.

In other words, patients should not assume their plan’s current process has already changed.

What readers can do now

If a prescription is delayed, ask the pharmacy whether prior authorization is the reason and whether the prescriber has been contacted. If you are covering a medicine through a health plan, it can also help to ask whether a faster review is possible and what information the plan needs.

Keep copies of denial letters, appeal notices, and any messages from the plan or clinic. Those records can be useful if the request needs to be appealed or resubmitted.

For people with chronic conditions, it may be worth checking ahead on medicines that routinely need approval so gaps in treatment are less likely.

The bottom line

CMS is trying to make drug prior authorization faster, more digital, and easier to follow. If the rule is finalized, some patients may experience fewer pharmacy delays and clearer plan decisions. For now, though, it remains a proposal.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.